CDISC CDASH.

2. Baseline Clinical Characteristics:

This includes disease-specific variables collected at enrollment, such as:

• Diagnosis date and criteria
• Clinical severity scales (e.g., NYHA Class, ECOG)
• Comorbidities and past medical history
• Baseline laboratory or biomarker values

These form the foundation for longitudinal tracking and comparisons over time, enhancing the value of Stability Studies that assess product longevity and patient outcomes.

3. Treatment and Medication Exposure Data:

Understanding treatment pathways is central to any registry. Include:

• Drug name, dosage, and administration route
• Start and stop dates of therapy
• Treatment adherence or persistence metrics
• Reasons for discontinuation or switching

Capture product lot numbers and expiry dates where possible, which supports GMP documentation and traceability in case of safety signals.

4. Outcomes and Follow-Up Variables:

Outcomes are the heart of real-world evidence. Define clear primary and secondary endpoints, such as:

• Survival or time-to-event metrics
• Disease progression or remission criteria
• Hospitalizations and emergency visits
• Lab values and imaging results at intervals

Ensure consistency across follow-up visits and harmonize timeframes across study sites.

5. Adverse Events and Safety Monitoring:

Capture adverse events (AEs) and serious adverse events (SAEs) using standardized fields:

• AE term (MedDRA coded)
• Onset and resolution dates
• Severity and seriousness
• Relationship to study product
• Outcome of the AE

Document according to SOPs and include pharma SOP checklist requirements to ensure inspection readiness.

6. Patient-Reported Outcomes and Quality of Life:

Include instruments validated for the target population:

• EQ-5D, SF-36, or disease-specific PROs
• Pain scales or fatigue scores
• Adherence and satisfaction surveys

Use electronic capture tools for efficiency and improved patient engagement.

7. Healthcare Resource Utilization and Costs:

These elements support economic evaluations and HTA submissions:

• Hospital stays, length of stay
• Outpatient visits and diagnostic tests
• Direct and indirect costs (optional)

These data help demonstrate real-world value to payers and policymakers.

Standardization and Interoperability:

For the data to be useful across systems and countries, apply consistent data standards:

• Use CDISC for structure
• Follow MedDRA and WHO-DD for coding
• Define variable formats (e.g., date formats, units)

Implementing these guidelines ensures smooth integration with EHRs and facilitates data sharing initiatives supported by computer system validation protocols.

Quality Control and Audit Readiness:

Data integrity is essential for regulatory and clinical acceptability. Put in place:

• Pre-specified edit checks
• Audit trails and change logs
• Periodic monitoring and source data verification
• Training and certification for data entry personnel

These controls mirror those used in GMP training environments and foster credibility.

Regulatory Considerations:

Data elements must support compliance with regulatory requirements. Agencies like the Health Canada and EMA expect traceability and clarity in endpoint definitions. Avoid excessive data points that introduce noise; instead, focus on relevance and utility.

Conclusion:

A well-designed registry study relies on precise, purpose-driven data elements. From patient demographics to safety monitoring and quality-of-life measures, each variable plays a role in building a meaningful real-world dataset. Aligning registry design with regulatory expectations, data standards, and clinical priorities ensures the data you collect today serves as reliable evidence tomorrow. Build your registry with clarity, consistency, and compliance in mind—and you’ll be better positioned to generate valuable RWE that drives impact and innovation.